Shares of Seres Therapeutics Inc. MCRB, + 332.15% hit nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapy company reported faster results from a Phase 3 trial of its SER-109 for recurrent C. difficile infections (CDI), as an infection of the colon. Trading volume …
Read More »Seres Therapeutics stock rockets nearly quadrupled to positive Phase 3 data on treatment for obese infections
